RECRUITINGOBSERVATIONAL
Evaluation of Adherence, Persistence and Efficacy of Treatment With Alirocumab 300mg in Italy
Evaluation of Adherence, Persistence and Efficacy of Treatment With Alirocumab 300mg in Italy - The ALINET Registry
About This Trial
Evaluation of adherence, persistence and efficacy of treatment with alirocumab 300 mg in a real-life Italian population.
Who May Be Eligible (Plain English)
Who May Qualify:
\- Patients under alirocumab 300mg treatment.
Who Should NOT Join This Trial:
- Age \< 18 years o \> 80 years;
- Patients who refuse to participate and to sign willing to sign a consent form.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
\- Patients under alirocumab 300mg treatment.
Exclusion Criteria:
* Age \< 18 years o \> 80 years;
* Patients who refuse to participate and to sign informed consent.
Treatments Being Tested
DRUG
Praluent (Alirocumab)
Alirocumab 300 mg injection
Locations (1)
Federico II University of Naples, Department of Advanced Biomedical Sciences
Naples, Napoli, Italy